CTLA4 and neoplasm: Therefore, CSCs targeted therapies combined with FDA-approved PD-1/PD-L1 checkpoint inhibitors [157] or dual CTLA-4 blockade provided significant anti-tumor effects and CSC eradication [157, 158].